FLT3/CDK4-IN-1 is a potent, highly selective, and orally active dual FLT3/CDK4 inhibitor (IC50 values of 7 nM and 11 nM for FLT3 and CDK4, respectively); it exhibits antiproliferative activity against certain cancer cells and demonstrates favorable in vivo antitumor efficacy.